Becotatug Vedotin Phase 2 Hepatocellular Carcinoma Study
Summary
NIH registered a Phase 2 clinical trial (NCT07536789) for Becotatug vedotin (MRG003) in previously treated advanced hepatocellular carcinoma (HCC). The study will evaluate efficacy and safety of MRG003 as an intervention. No compliance obligations or deadlines are imposed by this registration.
What changed
NIH added a Phase 2 clinical trial registration for Becotatug vedotin (MRG003) targeting previously treated advanced hepatocellular carcinoma. The trial will assess efficacy and safety as a single intervention.\n\nPharmaceutical companies conducting oncology research may track this trial as part of competitive intelligence on HCC treatments. Healthcare providers monitoring clinical developments in liver cancer may note MRG003 as a potential future therapeutic option. This registration creates no immediate compliance obligations for regulated entities.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
Phase 2 NCT07536789 Kind: PHASE2 Apr 17, 2026
Abstract
This study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).
Conditions: Hepato Cellular Carcinoma (HCC)
Interventions: MRG003
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.